Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

BACKGROUND: We conducted a retrospective review of the dose, toxicity, and efficacy of second line gemcitabine plus nab-paclitaxel (G + Nab-P) after FOLFIRINOX in patients with metastatic and locally advanced unresectable pancreatic cancer. METHODS: In this retrospective study, we included all patie...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Exp Hematol Oncol
Hoofdauteurs: Zhang, Yue, Hochster, Howard, Stein, Stacey, Lacy, Jill
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2015
Onderwerpen:
Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4597390/
https://ncbi.nlm.nih.gov/pubmed/26451276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0025-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items